Plain-English translation of NCT07102264 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called CPMX1 that uses ultrasound to measure how hard or soft a thyroid nodule is. The device works similarly to how doctors examine patients by touch, but gives precise measurements. Researchers hope this new tool can better predict which thyroid nodules are actually cancer, helping avoid unnecessary surgeries for patients whose nodules are benign.
Many patients with uncertain thyroid nodules undergo surgery even though 75% of them don't actually have cancer. This new treatment could provide more accurate information upfront, helping doctors and patients make better decisions about whether surgery is truly necessary.
You likely qualify if…
You likely don't qualify if…
You would receive the standard ultrasound examination of your thyroid that you're already scheduled for, plus an additional measurement using the new CPMX1 device. The device gently applies pressure to your thyroid nodule to measure its compressibility—similar to how a doctor would examine it by hand, but with precise measurements. This extra measurement should take only a few minutes and causes no pain or harm.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Switzerland
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment target
~30 participants
Started
August 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
PD Dr. med. Urs Borner
Insel Gruppe AG, University Hospital Bern
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.